Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer SCLCmedulloblastoma and others.
Both the absolute and relative frequencies of lung cancer have risen dramatically. Currently, studies utilizing genomic and proteomic profiling technology are providing further insights into SCLC biology.
Lung cancer researchers and the pharmaceutical companies appear to be living in the land of the Lotus-Eaters. There is currently no consensus on how patients who relapse, or do not completely respond, after first-line treatment should be managed, although there is some evidence that second-line therapy with the same agents is worthwhile National Institute for Health and Clinical Excellence, ; novel agents are under investigation.
Certain intrinsic SCLC features serve as limitations in our efforts toward demonstrating its biological heterogeneity. There have been advances in the clinic since then, including the approval of topotecan for recurrent SCLC and the application of new radiation therapy strategies, but despite these advances the outlook for patients afflicted with SCLC remains dismal 3 - 8.
We calculated the proportion of people who had chemotherapy according to the patient, tumour and trust characteristics defined above and used multivariate logistic regression to estimate the odds of receiving chemotherapy according to the same characteristics.
Abstract Small cell lung cancer SCLC is an aggressive malignancy with a distinct natural history and dismal prognosis.
It is believed that only a small subset of the numerous somatic mutations observed in SCLC are crucial for tumor cell proliferation and progression. We enhanced our chemotherapy records by comparing records in HES and the NLCA and found that use of a single data set underestimated the proportion of people who received chemotherapy.
Discussion We have used current English data to describe which patients with SCLC received chemotherapy treatment and give real-life estimates of survival.
Strengths and limitations The main strengths of this study are the large sample size and the validity of the database Rich et al, b.
Conclusion These national data reflect the decisions that were made about chemotherapy treatment in clinical practice in England.